Antinociceptive tolerance to NSAIDs microinjected into dorsal hippocampus by Gulnazi Gurtskaia et al.
Gurtskaia et al. BMC Pharmacology and Toxicology 2014, 15:10
http://www.biomedcentral.com/2050-6511/15/10RESEARCH ARTICLE Open AccessAntinociceptive tolerance to NSAIDs
microinjected into dorsal hippocampus
Gulnazi Gurtskaia, Nana Tsiklauri, Ivliane Nozadze, Marina Nebieridze and Merab G Tsagareli*Abstract
Background: Pain is characterized as a complex experience, dependent not only on the regulation of nociceptive
sensory systems, but also on the activation of mechanisms that control emotional processes in limbic brain areas
such as the amygdala and the hippocampus. Several lines of investigations have shown that in some brain areas,
particularly the midbrain periaqueductal gray matter, rostral ventro-medial medulla, central nucleus of amygdala and
nucleus raphe magnus, microinjections of non-steroidal anti-inflammatory drugs (NSAIDs) induce antinociception with
distinct development of tolerance. The present study was designed to examine whether microinjection of NSAIDs,
clodifen, ketorolac and xefocam into the dorsal hippocampus (DH) leads to the development of antinociceptive
tolerance in male rats.
Methods: The experiments were carried out on experimental and control (with saline) white male rats. Animals
were implanted with a guide cannula in the DH and tested for antinociception following microinjection of
NSAIDs into the DH in the tail-flick (TF) and hot plate (HP) tests. Repeated measures of analysis of variance with
post-hoc Tukey-Kramer multiple comparison tests were used for statistical evaluations.
Results: We found that microinjection of these NSAIDs into the DH induces antinociception as revealed by a
latency increase in the TF and HP tests compared to controls treated with saline into the DH. Subsequent tests
on days 2 and 3, however, showed that the antinociceptive effect of NSAIDs progressively decreased, suggesting
tolerance developed to this effect of NSAIDs. Both pretreatment and post-treatment with the opioid antagonist
naloxone into the DH significantly reduced the antinociceptive effect of NSAIDs in both pain models.
Conclusions: Our results indicate that microinjection of NSAIDs into the DH induces antinociception which is
mediated via the opioid system and exhibits tolerance.
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Emotional distress is an intrinsic and the most undesir-
able feature of painful states. Pain is characterized as a
complex experience, dependent not only on the regula-
tion of nociceptive sensory systems, but also on the acti-
vation of mechanisms that control emotional processes
in limbic brain areas such as the amygdala and the
hippocampus [1]. The involvement of the hippocampal
formation (HF) in nociception has been suggested in
several studies [2-4]. Just recently, some abnormalities in
hippocampal functioning with persistent pain have been
shown [5]. Particularly, mice with spared nerve injury* Correspondence: tsagareli@biphysiol.ge
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unless otherwise stated.(SNI) neuropathic pain were unable to extinguish con-
textual fear and showed increased anxiety-like behav-
ior. Additionally, mice with SNI compared with sham
animals exhibited hippocampal reduced extracellular
signal-regulated kinase expression and phosphorylation,
decreased neurogenesis, and altered short-term synaptic
plasticity [5].
Furthermore, morphine microinjections in the dorsal
hippocampus (DH) produced antinociceptive effects in
the formalin-induced orofacial pain model in rats [6].
Recent evidence suggests the participation of cholinergic,
opioidergic and GABA-ergic systems of the DH in the
modulation of nociception in guinea pigs [2]. Moreover,
opioid peptides are important modulators of information
processing in the hippocampus. When activated, opioidal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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anisms, and the HF is a structure that expresses significant
densities of this kind of receptors [7,8]. In addition, the
hippocampus is anatomically connected to components of
the pain neuromatrix, including the amygdala and the
descending pain pathway with the periaqueductal gray
(PAG) – the rostral ventromedial (RVM) region of me-
dulla [9]. However, specific neural substrates and circuitry
mediating opioid-induced hippocampal antinociception
are unknown.
We have recently shown that in the PAG, the central
nucleus of amygdala (CeA), and the nucleus raphe magnus
(NRM), microinjection of non-steroidal anti-inflammatory
drugs (NSAIDs) induces antinociception with some
effects of tolerance and cross-tolerance to morphine
[10-14]. These findings strongly support the suggestion
of endogenous opioid involvement in NSAIDs antino-
ciception and tolerance in the descending pain-control
system [15-19]. However, involvement of NSAIDs anti-
nociception in the HF is still a matter of controversy.
For example, indomethacin did not protect against sig-
nificant pain-induced down-regulation of neurokinin-1
(NK-1) and brain derived-neurotropic factor (BDNF)
receptor genes in the hippocampus, suggesting that al-
though analgesic drug treatment reduces nociceptive
sensory activation in the spinal cord, it is insufficient to
prevent the impact of pain on the hippocampus [20].
In this study, we have examined whether microinjec-
tion of the widely used NSAIDs diclofenac, ketorolac,
and xefocam into the DH induces antinociception and




The experiments were carried out on male Wistar rats,
200-250 g in body weight, bred at Beritashvili Center for
Experimental Biomedicine. The experimental protocol
was approved by the local Bioethic Committee of the
Center. Every effort was made to minimize both the num-
ber of animals used and their suffering. Guidelines of the
International Association for the Study of Pain regarding
animal experimentation were followed throughout [21].
Surgical procedures
Under anesthesia with thiopental (55 mg/kg, i.p. “Kievmed”,
Ukraine), a 12 mm-long stainless steel guide cannula
(Small Parts, Inc, USA) was stereotaxically implanted
into the DH bilaterally (AP:-4.3; L:±2.5; H:2.8) according
to the coordinates in the atlas of Paxinos and Watson [22]
siting the tip 2 mm above the DH. Guides were anchored
to the cranium by dental cement. The guide cannula was
plugged with a stainless steel stylet. Thereafter, the rats
were handled every day for 3 days for 15 min. During thistime, the stylet was removed and 14 mm-long stainless
steel microinjection cannula was inserted into the guide
cannula to reach the DH, but no drug was injected. This
helped to habituate the rats to the injection procedure and
to reduce artifacts arising from mechanical manipulation
during the test days. Five days after surgery a micro-
injection cannula, attached to a 50-μl Hamilton syringe
(Hamilton, Inc, USA), was introduced through the guide
cannula, and the drug was microinjected while the rat
was gently restrained.Drugs
Clodifen (diclofenac sodium, 75 μg/0.5 μl, RotexMedica,
Germany), ketorolac (ketorolac tromethamine, 90 μg/0.5 μl,
Zee Drugs, India) or xefocam (lornoxicam, 12 μg/0.5 μl,
Nycomed, Austria) were injected through the micro-
injection cannula; the guide cannula was then plugged
with a stainless steel stylet. Saline was injected in the
same volume (0.5 μl, GalichPharm, Ukraine) and man-
ner in a separate group of rats for controls. Solutions
were microinjected in about 10 seconds.Behavioral testing
Twenty minutes post microinjection, i.e. 10-min before
the peak of the drugs’ effect is normally reached, animals
were tested for antinociception using the tail-flick (TF)
and hot plate (HP) tests. For the TF test, the distal part
of the tail was stimulated with a light beam and the la-
tency measured until the tail was reflexively flicked away
from the beam (IITC #33, IITC Life Science, Inc.,
Woodland Hills, CA, USA). For the HP test, the rat was
placed on a 55ºC hot plate and the latency to the first
hindpaw licking or jumping was measured (IITC #39).
The cut-off time was 20 s for both TF and HP latencies.
Each rat was tested with both tail flick (TF) and hot
plate (HP) in the same session. A similar procedure was
followed for the repeated microinjection of clodifen,
ketorolac, xefocam or saline for four consecutive days.
In control experiments, saline microinjections into
the DH was followed by a non-selective opioid receptor
antagonist naloxone (0.5 μl, GalichPharm, Ukraine)
and tested for TF and HP latencies for the three con-
secutive days.
In the second set of experiments, twenty minutes after
NSAIDs administration we tested on whether post-
treatment with a non-selective opioid receptor antagonist
naloxone in the DH diminishes NSAID-induced antinoci-
ception on the 1st, 2nd and 3rd experimental days. In the
third set of experiments, rats pretreated with the same
dose of naloxone in the DH were followed by TF and HP
tests. 10 min after rats were treated with NSAIDs in the
same dose as in the first and second set of experiments
and were then tested again. Different animal groups were
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each group was five or six.
Histology
At the end of each set of experiments, the microinjec-
tion sites were marked with 2 μl of saturated solution
of Pontamine Sky Blue (Sigma Chemical, Co.) and the
animal was euthanized with an overdose of ester. After
fixation by immersion in 10% formalin, the brain was
sectioned and counterstained with Cresyl Violet. The
microinjection sites were histologically verified and plot-
ted according to Paxinos and Watson (1997) stereotaxic
atlas coordinates [22]. Representative microinjection sites
are shown in Figure 1.
Statistical analysis
All data are presented as mean±S.E.M. Repeated mea-
sures of analysis of variance (ANOVA) with post-hoc
Tukey-Kramer multiple comparison test were used for
statistical comparisons between treated and saline groups,
and treated and naloxone groups, respectively. TheFigure 1 Serial coronal sections of the rat brain showing placement o
to the right of sections represent millimeters relative to bregma, adapted fKolmogorov–Smirnov test was applied to verify normality.
The statistical software utilized was InStat 3.05 (GraphPad
Software, USA). Statistical significance between vehicle
control and treated groups, and naloxone and treated
groups of rats was acknowledged if P < 0.05.
Results
We found that microinjection of NSAIDs into the DH
produced antinociception as revealed by a latency increase
in TF and HP compared to the baseline control of intact
rats and a control group with saline microinjected into the
same site as well. The TF latency significantly increased
for clodifen [ANOVA: F(4, 16) = 20.189, P < 0.0001], ketor-
olac [ANOVA: F(4,20) = 22.314, P < 0.0001], and xefocam
[ANOVA: F(4,16) = 32.42, P < 0.0001]. We found simi-
lar significant differences in the HP latencies for clodi-
fen [ANOVA: F(4,16) = 21.53, P < 0.0001], for ketorolac
[ANOVA: F(4,20) = 17.764, P < 0.0001], and for xefocam
[ANOVA: F(4,16) = 39.463, P < 0.0001], respectively. Sub-
sequent NSAIDs microinjections caused progressively less
antinociception, so by day 4 there was no effect, similar tof microinjections bilaterally in the DH (black arrows). The numbers
rom the Paxinos and Watson (1997) stereotaxic atlas [22].
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(Figure 2).
Control testing with saline microinjections into the
DH followed by a non-selective opioid receptor antagon-
ist naloxone statistically did not change the latency to
respond in the TF [ANOVA: F(5,24) = 0.8914, P = 0.5024,
not significant] and HP [ANOVA: F(5,24) = 0.1463,
P = 0.9792, not significant] tests respectively for the
first, second and third days (P > 0.05) (Figure 3A, B).
In the second set of experiments, we tested if post-
treatment with the non-selective opioid receptor antag-
onist naloxone in the DH diminishes NSAID-induced
antinociception at the first, second and third experimen-
tal days. Twenty minutes after NSAID administration,
microinjection of naloxone in the DH significantly de-
creased antinociceptive effects of these drugs at the first
day in the TF for clodifen [ANOVA: F(5,20) = 26.906,Figure 2 Microinjections of NSAIDs into the DH for four
consecutive days result in a progressive decrease in TF (A)
and HP (B) latencies as compared to vehicle saline control.
The number of rats in the control group N = 16/group, in the treated
groups for clodifen N = 5/group, for ketorolac N = 6/group, and for
xefocam N= 5/group, respectively. *- P < 0.05, **- P < 0.01, ***- P < 0.001.
Figure 3 Control experiments of post-treatment with naloxone
after microinjection of saline into the DH does not significantly
change TF (A) and HP (B) latencies either for the first or second
and third days (P > 0.05). Number of rats N = 5/group.P < 0.0001], (t = 13.161, P < 0.001) (Figure 4A), for ketoro-
lac [ANOVA: F(5,20) = 24.701, P < 0.0001], (t = 10.691,
P < 0.001) (Figure 4B), and for xefocam [ANOVA:
F(5,20) = 22.412, P < 0.0001], (t = 9.745, P < 0.001) (Figure 4C).
At the second and third experimental days, naloxone
showed generally trend effects (Figure 4), except for
xefocam at the second experimental day where the dif-
ference between xefocam and naloxone injected groups
is significant (P < 0.05) (Figure 4C).
The same effects we discovered in the HP test for clo-
difen [ANOVA: F(5,20) = 11.341, P < 0.0001], (t = 6.679,
P < 0.01) (Figure 4D), for ketorolac [ANOVA: F(5,20) =
33.093, P < 0.0001], (t = 12.141, P < 0.001) (Figure 4E),
and for xefocam [ANOVA: F(5,20) = 35.494, P < 0.0001],
(t = 13.068, P < 0.001) (Figure 4F, C). At the second and
third experimental days, naloxone showed generally trend
effects (Figure 4), except for ketorolac in the second ex-
perimental day where the difference between ketorolac
and naloxone injected groups is significant (P < 0.01)
(Figure 4E).
In the third set of experiments, we tested if pretreat-
ment with naloxone prevents antinociception induced
by NSAID microinjected into the DH. Pretreatment with
Figure 4 Post treatment with naloxone after microinjections of NSAIDs into the DH results in a significant decrease in TF latency for
the first day for clodifen (A), ketorolac (B), and xefocam (C), respectively (P < 0.001). On the second and third days, there are generally
trend effects for all three non-opioid analgesics. The same decreases of latencies are observed in HP test for clodifen (D) (P < 0.01), ketorolac
(E) (P < 0.001), and xefocam (F) (P < 0.001), respectively. Number of rats N = 5/groups. *- P < 0.05, **- P < 0.01, ***- P < 0.001.
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clodifen (Figure 5A), ketorolac (Figure 5B), and xefocam
(Figure 5C) in the TF test. The differences between
NSAIDs injected and naloxone injected groups are not
significant (Figure 5). The same results are in the HP
test for clodifen (Figure 6A), ketorolac (Figure 6B), and
xefocam (Figure 6C), respectively.
Discussion
The present results demonstrate that microinjections of
the NSAIDs, clodifen, ketorolac and xefocam into the DH
induce antinociception. This confirms our and other col-
leagues previous results with systemic, intraperitoneal ad-
ministration of NSAIDs [23,24], and results using
microinjection of the same NSAIDs into the PAG [15,16].
In the other experiments in rats, responses of spinal dorsal
horn wide-dynamic range neurons to mechanical noxiousstimulation of a hindpaw were strongly inhibited by intra-
venous dipyrone (metamizol) [25].
Importantly, repeated microinjections of NSAIDs into
the DH resulted in a progressive decrease in antinociceptive
effectiveness, i.e. induced tolerance similar to that observed
with intra-PAG, CeA and NRM injections [11,12,14-17],
and reminiscent of the effect of opiates. For example, it has
recently been shown that repeated intrathecal injections of
a selective delta opioid receptor (DOPR) agonists deltor-
phin II or morphine induce tolerance effects on antihyper-
algesic and antinociceptive responses in rodents [26].
A major involvement of opioidergic mechanisms in toler-
ance to the analgesic effect of NSAIDs is unusual, because
traditionally the cellular and molecular actions of opioids
were thought to differ from those of non-opioid analgesics.
However, one interesting aspect of NSAIDs administration,




























































Figure 5 Experiments of pretreatment with naloxone before
microinjections of NSAIDs into the DH results in prevention
of NSAID-induced antinociception in TF latency for clodifen
(A), ketorolac (B), and xefocam (C), respectively. Number of

































































Figure 6 Experiments of pretreatment with naloxone before
microinjections of NSAIDs into the DH results in prevention
of NSAID-induced antinociception in HP latency for clodifen
(A), ketorolac (B), and xefocam (C), respectively. Number of
rats N = 5/groups.
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[13,15,16,18], or into CeA [11,18], progressively led to a
loss of their antinociceptive effects, i.e. produced toler-
ance. Furthermore, tolerance to metamizol was accom-
panied by cross-tolerance to morphine as if opioid
analgesics had been repeatedly administered [16,17].
The mechanism producing tolerance to NSAIDs can be
due to the participation of endogenous opioids [19,27,28].
Herein we clearly showed that a non-selective opioid
receptor antagonist naloxone significantly diminishesNSAIDs-induced antinociception on the first day, and
on the second and third days shows trend effects. Our
findings affirm the results of other investigators that
microinjection of dipyrone and aspirin, and systemic
dipyrone are abolished by systemically injected and/or
microinjections of the opioid antagonists, naloxone,
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[15,23,25,27]. The latter is a cyclic analog of the neuropep-
tide somatostatin and is known to block the analgesic ef-
fect of morphine [15]. Moreover, endogenous opioids are
involved in the potentiation of analgesia observed with the
combination of morphine plus dipyrone (metamizol). The
release of endogenous opioids by dipyrone could enhance
exogenous opiate effects, explaining the need for more na-
loxone to counteract the antinociception produced by
morphine plus dipyrone [27].
The mechanisms whereby NSAIDs, in general, engage
endogenous opioids are not completely understood. There
is a proposed model for the PAG where γ-amino-butyric
acid (GABA) containing synapses act as the plausible site
where NSAIDs could converge with endogenous opioids.
The PAG output neurons that drive antinociception via
downstream relays, like the RVM, is tonically inhibited
by local GABA-ergic synapses [19,28]. Endogenous opi-
oids reduce presynaptic release of GABA in the PAG.
Furthermore, activation of μ-opioid receptors in the
PAG brings about an elevation of the intracellular con-
centration of arachidonic acid metabolites. One of the
pathways leads to the formation of hepoxilins, which
increase potassium conductance. This in turn hyperpolar-
izes the presynaptic GABA-ergic terminals and decreases
GABA release [29]. Disinhibition of PAG output neurons
would thus drive antinociception in the downstream loop
of the PAG–RVM–spinal dorsal horn [30,31]. For this
pathway to function, however, an activation of μ-opioid
receptors seems to be necessary, because naloxone or
CTOP blocks the effect of PAG-microinjected metamizol
or aspirin [15,23].
As stated above, the action of either opioid or non-
opioid analgesics in the PAG leads to an excitation of
PAG output neurons and this causes an activation of
RVM off-cells and an inhibition of RVM on-cells, thus
leading to antinociception (analgesia). When tolerance
develops, PAG microinjections of morphine [32], or
metamizol [15], are no longer capable of affecting RVM
neurons and inducing analgesia. These results show fur-
ther neuronal relationships between opioid and non-
opioid analgesics as regards the descending pain-control
and modulation system [19,30]. In addition, metamizol
probably can act via endocannabinoids in the downstream
PAG-RVM axis reducing inflammation pain in rats [33].
There is evidence that GABAergic mediation of opioid
effects is a widespread phenomenon and occurs through-
out most of CNS. A co-localization between hippocampal
μ-opioid receptors and GABA-ergic interneurons in CA1,
CA3 and dentate gyrus has been shown in rats [34]. The
localization of μ-opioid receptors on GABA-ergic neurons
suggests that these receptors, when activated, can directly
control the hippocampal GABA-ergic neurons’ activity
[34,35]. Several studies have shown that activation of theopioid receptors can lead to the inhibition of interneuron
activity resulting in diminished GABA release and the
disinhibition of hippocampal pyramidal neurons [36-38].
Our results support the hypothesis that modulation of
nociceptive response in the DH could occur in a manner
similar to that proposed for the PAG [9,19,28,39]. It is
therefore likely that in this study the antinociception
observed after microinjection of NSAIDs into the DH
occurs through the inhibition of tonically active GABA-
ergic interneurons. In addition, involvement of the down-
stream PAG-RVM axis mechanism is also possible.
Conclusions
In conclusion, our data showed for the first time that
repeated microinjections of NSAIDs into the DH induce
antinociception that is opioid mediated. These findings
confirmed previous studies indicating that the antinoci-
ceptive action of NSAIDs may be mediated via the en-
dogenous opioid system, as it is blocked by naloxone
and exhibits tolerance.
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